<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04054115</url>
  </required_header>
  <id_info>
    <org_study_id>1000060394</org_study_id>
    <nct_id>NCT04054115</nct_id>
  </id_info>
  <brief_title>Acute Effects of the Prostaglandin (Alprostadil) on Cerebral and Pulmonary Flow</brief_title>
  <acronym>Alprostadil</acronym>
  <official_title>The Acute Effects of the Prostaglandin (Alprostadil) on Cerebral and Pulmonary Flow After the Bidirectional Cavopulmonary Connection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Hospital for Sick Children</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The second stage operation towards single ventricle palliation is 'bidirectional
      cavopulmonary connection' (BCPC). The superior vena cava is connected to the pulmonary
      artery, diverting 'blue' blood from the upper body (including the brain) to the lungs. A
      successful BCPC requires sufficient and easy blood flow through the lungs. Alprostadil is the
      synthetic form of prostaglandin (hormone that causes dilation of blood vessels) and has been
      shown to increase blood flow in the brain hence increasing blood flow to the lungs after
      BCPC, potentially useful in managing children post BCPC with low flow to the lungs and thus
      poor oxygenation. This study propose to investigate acute effects of Alprostadil on different
      blood vessels after BCPC.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 23, 2019</start_date>
  <completion_date type="Anticipated">December 23, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 23, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Patients with a bidirectional Glenn in their Pre-Fontan evaluation.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cerebral blood flow</measure>
    <time_frame>will be measured 30-40 mins after infusion of alprostadil</time_frame>
    <description>Cerebral blood flow</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Congenital Heart Disease</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baseline cardiac catheterization under GA. (Standard of Care, SOC)
Transfer patient to MRI unit
Baseline MRI
Obtain ABG for pCO2 from existing femoral arterial access.
Repeat pressure measurements with existing catheters at the SVC, RA and Aorta.
MRI phase contrast imaging for flow measurements(SOC).
During the MRI, Alprostadil infusion will be started and titrated to the target dose 0.1mcg/kg/min, provided there is a less than 20% drop in blood pressure from baseline.
Post alprostadil infusion
1ml blood sample taken from existing femoral venous access for prostaglandin level.
Repeat pressure measurements with existing catheters left at the SVC, RA and Aorta.
Repeat MRI flow measurements
7.Return to cath lab if further intervention required. 8.Recovery and monitoring for for 4 to 6 hours prior to discharge(SOC).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alprostadil 5 MCG Injection</intervention_name>
    <description>During the MRI, Alprostadil infusion will be started and titrated to the target dose, ensuring there is a less than 20% drop in blood pressure from baseline. Repeat pressure and MRI flow measurements once Alprostadil reaches 0.1mcg/kg/min.</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:• BCPC patients at time of routine pre-Fontan assessment: Cardiac
        catheterization and cardiac magnetic resonance imaging (CMR)

        • Patients between the ages of 1 and 6 years old.

        Exclusion Criteria:

          -  Patients who are hypersensitive to this product or to any ingredient in its
             formulation.

          -  Patients with seizure disorders or coagulopathies.

          -  Patients with abnormal kidney function.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rajiv Chaturvedi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Hospital for Sick Children</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rajiv Chaturvedi, MD</last_name>
    <phone>416-813-7654</phone>
    <phone_ext>206141</phone_ext>
    <email>rajiv.chaturvedi@sickkids.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>L4K4x6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajiv Chaturvedi, MD</last_name>
      <phone>416-813-7654</phone>
      <phone_ext>206141</phone_ext>
      <email>rajiv.chaturvedi@sickkids.ca</email>
    </contact>
    <investigator>
      <last_name>David Faraoni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vannessa Chin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lars GrosseWortmann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christopher Lam, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sok-Leng Kang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 9, 2019</study_first_submitted>
  <study_first_submitted_qc>August 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2019</study_first_posted>
  <last_update_submitted>August 12, 2019</last_update_submitted>
  <last_update_submitted_qc>August 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Hospital for Sick Children</investigator_affiliation>
    <investigator_full_name>Rajiv Chaturvedi</investigator_full_name>
    <investigator_title>Staff Cardiologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alprostadil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

